Get the Stockscreener App
1.015
2.04%
-0.015
Adicet Bio Inc stock is traded at $1.015, with a volume of 888.16K.
It is down -2.04% in the last 24 hours and up +2.75% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$1.03
Open:
$1.06
24h Volume:
888.16K
Relative Volume:
0.97
Market Cap:
$84.87M
Revenue:
$38.70M
Net Income/Loss:
$-117.88M
P/E Ratio:
-0.5971
EPS:
-1.7
Net Cash Flow:
$-92.84M
1W Performance:
+14.01%
1M Performance:
+2.75%
6M Performance:
-24.70%
1Y Performance:
-68.57%
1-Day Range:
$1.00
$1.06
1-Week Range:
$0.85
$1.09
52-Week Range:
$0.81
$3.5001
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
1.015 | 84.87M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.06 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Top investors say Adicet Bio Inc (ACET) ticks everything they need - SETE News
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease - geneonline
Adicet Bio Inc [NASDAQ: ACET] Sees Increase in Stock Value - Knox Daily
Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Adicet Bio's (ACET) Market Perform Rating Reaffirmed at JMP Securities - MarketBeat
Adicet Bio reports progress in clinical trial enrollments By Investing.com - Investing.com Australia
Adicet Bio Inc (ACET) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Adicet Bio's (ACET) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Adicet Bio Inc (ACET) Stock Price and Analyst Predictions - The News Heater
What is ACET’s price-to-sales ratio telling us about the company’s value? - US Post News
Adicet Bio reports progress in clinical trial enrollments - Investing.com India
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Marketscreener.com
Revolutionary Lupus Treatment Gets FDA Fast-Track: Adicet's ADI-001 Could Transform Patient Care - StockTitan
JPMorgan Chase & Co. Boosts Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Sparks Excitement with Major Stock Options Award for New Hires! - Mi Valle
Adicet's New CMO Receives 750,000 Share Options Package as Company Bolsters Leadership - StockTitan
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - MSN
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Business Wire
Gamma Delta T Cell Pioneer Adicet Bio Takes Center Stage at Elite Biotech Conference - StockTitan
HC Wainwright & Co. Downgrades Adicet Bio (ACET) - MSN
Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by Jane Street Group LLC - Defense World
Geode Capital Management LLC Increases Position in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
Adicet Bio, Inc. (NASDAQ:ACET) Stake Reduced by State Street Corp - Defense World
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World
Adicet Bio begins trial for kidney cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat
Adicet Bio begins trial for kidney cancer therapy - Investing.com
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - BioSpace
ACET stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ACET stock touches 52-week low at $0.89 amid market challenges - Investing.com Canada
Adicet Bio names new Chief Medical Officer By Investing.com - Investing.com Australia
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - BioSpace
Adicet Bio Names Dr. Julia Maltzman As Chief Medical Officer - Contract Pharma
Adicet Bio names new Chief Medical Officer - Investing.com
Adicet Bio Names Dr. Julia Maltzman as Chief Medical Officer - Contract Pharma
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com Canada
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 18.1% - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces CAR-T challenges - Investing.com
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Rises By 6.1% - MarketBeat
Adicet Bio Awards New Employee Stock Options at $1.13 Per Share in Inducement Grant | ACET Stock News - StockTitan
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):